Class / Patent application number | Description | Number of patent applications / Date published |
514223200 | 1,2,4 - Benzothiadiazine - 1,1 - dioxides (including hydrogenated) | 67 |
20080300239 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives. | 12-04-2008 |
20080312218 | FUSED TETRACYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS - In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimers disease. | 12-18-2008 |
20090012067 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels - Provided are methods of increasing K | 01-08-2009 |
20090062263 | 4-Hydroxy-5,6-dihydro-1H-pyridin-2-one compounds - The invention is directed to 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 03-05-2009 |
20090062264 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain salts of K | 03-05-2009 |
20090111798 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 04-30-2009 |
20090325941 | NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES - The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith. | 12-31-2009 |
20100009974 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them - Compounds of formula (I): | 01-14-2010 |
20100035866 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - The present invention relates to compounds of substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-ones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-ones according to the present invention have excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors. Also, the compounds reverse a disruption of PPI by apomorphine and don't show rotatod deficit in mice. Therefore the compounds according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders. | 02-11-2010 |
20100120753 | Anti-Infective Agents - The present invention provides HCV polymerase inhibiting compounds having the formula (I): | 05-13-2010 |
20100160300 | Method of Treating Depression - Methods for treatment of depression-related mood disorders in mammals, particularly humans are disclosed. The methods of the invention include administration of compounds capable of enhancing glutamate transporter activity in the brain of mammals suffering from depression. ATP-sensitive K | 06-24-2010 |
20100234362 | USE OF DIAZOXIDE FOR SUPPRESSING THE PLASMA INSULIN LEVEL IN A MAMMAL - The present invention relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof, wherein the fasting and/or postabsorptive plasma insulin level is reduced to about 5 mU/l or less. The present invention also relates to the use of a potassium channel activator in the manufacture of a medicament for suppressing the fasting plasma insulin level and/or postabsorptive insulin level in a mammal in need thereof for treating or preventing obesity, obesity related disorders and conditions and other disorders and conditions related to weight gain in a mammal in need thereof, said method comprising orally administering to said mammal in need thereof a daily dosage of about 5 mg to about 1200 mg, calculated on a Diazoxide active weight basis. | 09-16-2010 |
20100273784 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS - Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions. | 10-28-2010 |
20100324029 | THERAPEUTIC AGENTS - The invention encompasses 2-[4-(imidazolyl)-phenyl]vinyl-heterocycle derivatives which selectively attenuate production of Abeta(1-42) and are useful in the treatment of Alzheimer's disease. Pharmaceutical compositions and methods of use are also encompassed. | 12-23-2010 |
20110218190 | THERAPEUTIC USES OF AMPA RECEPTOR MODULATORS FOR TREATMENT OF MOTOR DYSFUNCTION - The application describes treatment of motoneuronal dysfunctions or disorders using AMPA receptor modulators. Examples of a motoneuronal dysfunction or disorder include obstructive sleep apnea, snoring, multiple sclerosis, spinal cord injury, e.g., crush, partial or complete transection, motor neuron diseases, motor weakness due to aging, stroke, tumor, hemorrhage, degenerative or wasting diseases, and spasticity. One example of an AMPA receptor modulator is a benzothiadiazide compound. Another example of an AMPA receptor modulator is an ampakine. Yet another example of an AMPA receptor modulator is aniracetam. | 09-08-2011 |
20110263579 | CHLOROTHIAZIDE, CHLOROTHIAZIDE SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to an improved process for the preparation of Chlorothiazide and pharmaceutically acceptable salts thereof. The present invention relates to novel polymorphs of Chlorothiazide and Chlorothiazide salts, in particular Chlorothiazide sodium. The present invention further relates to pharmaceutical compositions comprising Chlorothiazide and Chlorothiazide salts, in particular Chlorothiazide sodium and process for preparation thereof. | 10-27-2011 |
20120165321 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives. | 06-28-2012 |
20120270863 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS - The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders. | 10-25-2012 |
20120295895 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS - A method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina, the method comprising administering to the subject a therapeutically effective amount of a primary amine compound of formula: | 11-22-2012 |
20120329786 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders. | 12-27-2012 |
20130059841 | THERAPEUTIC COMPOSITIONS AND METHODS - The present invention relates in general to therapeutic compositions and methods of use. In preferred embodiments, the invention relates to the field of eye health. In some embodiments, the invention relates to the prevention and treatment of macular degeneration by administering compounds disclosed herein. In some embodiments, the invention relates to compositions and methods of improving vision. | 03-07-2013 |
20130123244 | Hetero-Bicyclic Derivatives as HCV Inhibitors - Inhibitors of HCV replication of formula I | 05-16-2013 |
20130143873 | Diazoxide For Use In The Treatment Of Amyotrophic Lateral Sclerosis (ALS) - The invention relates to the diazoxide or a pharmaceutically acceptable salt thereof for use as a medicament at low doses to treat amyotrophic lateral sclerosis. | 06-06-2013 |
20130338151 | FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS - The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders. | 12-19-2013 |
20140031346 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I | 01-30-2014 |
20140350001 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain potassium ATP (K | 11-27-2014 |
20150051197 | HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD) and the like. The compound represented by formula (I): | 02-19-2015 |
20150126497 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute hypertension or malignant hypertension, hypoglycemia in disease states such as insulinoma (a tumor producing insulin) or congenital hyperinsulinism, hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia and cardiovascular complications. | 05-07-2015 |
20150126498 | OREXIN RECEPTOR ANTAGONISTS - The disclosures herein relate to novel compounds of formula wherein W, X and Y | 05-07-2015 |
20150320680 | INJECTABLE COMPOSITION CONTAINING CHLOROTHIAZIDE - The present invention relates to stable ready to use injectable liquid composition of chlorothiazide or its pharmaceutically acceptable salts. | 11-12-2015 |
20150353538 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders. | 12-10-2015 |
20150368269 | Factor IXa Inhibitors - The present invention provides a compound of Formula (I) | 12-24-2015 |
514223500 | With additional active ingredient | 35 |
20080214529 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS - The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 09-04-2008 |
20080227774 | 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS - The invention is directed to 5,5-disubstituted-indolizinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 09-18-2008 |
20080255101 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed. | 10-16-2008 |
20080261959 | Novel crystalline forms of (S)-N-(1-Carboxy-2-methyl-prop-1-y)-N-pentanoyl-N[2'-(1H-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine - This invention relates to novel crystalline forms of valsartan, namely Form A, Form B, Form C, Form D and their solvates thereof. Processes for the preparation of the novel forms are also provided. The present invention further relates to novel processes for preparing a stable amorphous form of valsartan, and in this connection, to the amorphous form of valsartan produced by such processes. The present invention also discloses a novel process for obtaining stable Form I crystals of valsartan. | 10-23-2008 |
20080275032 | Pyridazinone compounds - The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 11-06-2008 |
20090023714 | COMBINED PREPARATION OF A THIAZIDE DIURETIC AND A LOOP DIURETIC - The invention relates to pharmaceutical preparations which contain a combination of a thiazide diuretic and a low-dose loop diuretic and which are particularly useful for treating hypertension and heart failure. It is not only the overall natriuretic/diuretic effects which are increased due to said combination of thiazide diuretic and loop diuretic, but the undesired secondary effects regarding potassium and magnesium losses are significantly reduced as well. As a result, the desired hypocalciuric effect of the thiazide is maintained despite the presence of the loop diuretic. | 01-22-2009 |
20090036432 | Combinations of AT1-antagonists, amiloride or triamterine, and a diuretic - The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising
| 02-05-2009 |
20090149451 | PHARMACEUTICAL FORMULATIONS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain potassium ATP (K | 06-11-2009 |
20090156585 | ORGANIC COMPOUNDS - A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension. | 06-18-2009 |
20090203679 | GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of HCTZ and a hydrophilic filler selected from the group a carbohydrate or combinations thereof, e.g. sugars, sugar alcohols and starches or combinations of these. | 08-13-2009 |
20090215755 | USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICINAL PRODUCTS THAT ARE USEFUL IN THE PREVENTION AND TREATMENT OF DYSLIPIDAEMIAS AND OF DISEASES RELATED TO DYSLIPIDAEMIAS AND/OR TO OBESITY - Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB | 08-27-2009 |
20090312311 | COMBINATION OF ORGANIC COMPOUNDS - The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases | 12-17-2009 |
20100137289 | Methods and Compositions for Ameliorating Thiazide Induced Hyperlipidemia - Male Disclosed herein are compositions for ameliorating the lipid producing effects of thiazide therapy. Particularly exemplified herein are compositions containing a thiazide and allopurinol, or some other xanthine oxidase inhibitor. | 06-03-2010 |
20100184750 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 07-22-2010 |
20100280016 | PYRAZOLINE COMPOUNDS - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: | 11-04-2010 |
20110136793 | AMELIORATING DRUG-INDUCED ELEVATIONS IN BLOOD PRESSURE BY ADJUNCTIVE USE OF ANTIHYPERTENSIVE DRUGS - Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are atrisk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies. | 06-09-2011 |
20110190277 | PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY OR RENAL DISEASES - A method for the prevention or treatment of a cardiovascular, cardiopulmonary, or renal disease or condition in a human or mammal patient, the method comprising administering to the patient in need thereof an effective amount of: (a) telmisartan or a polymorph or salt thereof; and (b) simvastatin. | 08-04-2011 |
20110207724 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE WHICH COMBINE NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS WITH ANIT-HYPERTENSIVE COMPOUNDS - An oral dosage form of a non-steroidal anti-inflammatory drug (NSAID) is rendered safer for extended or chronic use for anti-inflammatory, analgesic or antipyretic therapy by combining it with an antihypertensive drug. The antihypertensive drug acts prophylactically to inhibit or reduce NSAID-induced hypertension and by so doing the adverse cardiovascular side effects of NSAIDs, such as high blood pressure, heart attack, stroke, opththamologic complications, and death, when NSAIDs are used repetitively over an extended period of time for reducing inflammation or in pain management. | 08-25-2011 |
20110312947 | Method of improving -adrenergic receptor function - The present invention relates to a method of increasing the sensitivity of a hyperinsulinemic patient to the anti-obesity and antidiabetic effects of a β adrenergic receptor (βAR) agonist. The method comprises administering to the patient the βAR agonist and an agent that reduces plasma insulin levels and thereby increases the sensitivity of the patient to the effects of the βAR agonist. | 12-22-2011 |
20120071470 | PHARMACEUTICAL COMPOSITION COMPRISING A RENIN INHIBITOR, A CALCIUM CHANNEL BLOCKER AND A DIURETIC - The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and a diuretic and to a method of using such composition for the treatment of cardiovascular disease. | 03-22-2012 |
20120115854 | PHARMACEUTICAL COMPOSITION CONTAINING ANTIHYPERTENSIVE AGENTS - The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases. | 05-10-2012 |
20120238554 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain salts of K | 09-20-2012 |
20120238555 | Pharmaceutical composition containing irbesartan - This invention relates to pharmaceutical compositions containing irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which exhibits a dissolution profile according to which greater than about 85% of the Irbesartan is dissolved within about 30 minutes using USP apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37° C. with paddle speed of 50 rpm. The formulation can optionally contain at least one additional active ingredient. | 09-20-2012 |
20120283251 | DEUTERATED 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to deuterated 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 11-08-2012 |
20120302555 | METHOD OF TREATMENT USING EPROSARTAN - The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (AII) receptors, and particularly selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, by administering to a subject in need thereof an effective dose of an eprosartan compound. With reference to the Recommended Effective Daily Dose of 600 mg, calculated on the basis of eprosartan administered in the form of eprosartan mesylate, it has now been found that a lower dose of eprosartan can be administered when the eprosartan compound is eprosartan acid. This dose is in the range of from 410 to 490 mg, most preferably about 450 mg. | 11-29-2012 |
20120316156 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID - The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a [1,2,4]thiadiazine 1,1-dioxide compound. | 12-13-2012 |
20130040942 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain salts of K | 02-14-2013 |
20130109680 | METHODS AND COMPOSITIONS FOR AMELIORATING THIAZIDE INDUCED HYPERLIPIDEMIA | 05-02-2013 |
20140171424 | HYPERTENSION AND HYPERURICEMIA - A method for treating hypertension in a subject in need thereof (e.g., wherein said treatment does not result in an increase in serum uric acid levels, abnormally elevated serum uric acid levels, hyperuricemia, serum uric acid levels of above 6 mg/dL, or in the development of gout in the subject), the method comprising administering to the subject: a. a thiazide diuretic; and b. an organic anion transporter 4 (OAT4) inhibitor. The thiazide diuretic is selected from hydrochlorothiazide, bendroflumethiazide, benzothiadiazine, hydroflumethiazide, clorothiazide, methyclothiazide, polythiazide, chlorthalidone, metolazone, indapamide, bumetanide, ethacrynic acid, furosemide or torsemide. The OAT4 inhibitor is 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid or a pharmaceutically acceptable salt thereof. | 06-19-2014 |
20140221358 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND DIAZOXIDE AND METHODS OF USE THEREOF - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 08-07-2014 |
20140296224 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives. | 10-02-2014 |
20140296225 | Inhibitors of the Renal Outer Medullary Potassium Channel - The present invention provides compounds of Formula I | 10-02-2014 |
20140357626 | Hetero-Bicyclic Derivatives As HCV Inhibitors - Inhibitors of HCV replication of formula I, including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R′ have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy. | 12-04-2014 |
20140364425 | SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF - Provided are immediate or prolonged administration of certain salts of K | 12-11-2014 |
20150065492 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS - The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus. | 03-05-2015 |